tbuckley/cabot-search huggingface dataset:
Abstract IA23: Metabolic complexity in cancer cells and tumors
Authors: Ralph J. DeBerardinis
Journal: Cancer Research (2018)

Abstract Metabolism is dynamic and responds to a wide range of cell-intrinsic and cell-extrinsic factors. In cancer, cell-intrinsic influences on metabolism include somatically acquired mutations in oncogenes and tumor suppressor genes, many of which regulate metabolic activity. Cell-extrinsic factors include nutrient access, which may become limiting due to inadequate vasculature and intense fuel utilization, and metabolic interactions with stromal and immune cells. A major challenge in cancer metabolism research is to understand how these various factors culminate in the metabolic phenotype of an intact tumor, and ultimately to identify which altered pathways represent potential therapeutic targets. We have taken two parallel approaches to understand metabolic complexity in human cancer. The first uses a combination of multiparametric imaging and intraoperative stable isotope infusions to assess metabolic fluxes in patients with solid tumors, and to compare fluxes between tumors and adjacent benign tissue. Genomic, histologic, and metabolic analysis of tumor samples allows us to correlate various intrinsic and extrinsic factors to specific aspects of the metabolic phenotype. The second approach uses standardized culture conditions to assess cell-intrinsic heterogeneity of metabolic preferences and dependencies in large panels of human cancer cell lines. This approach has uncovered liabilities associated with specific molecular subtypes of non-small cell and small cell lung cancer. I will discuss the application of these two approaches to metabolic heterogeneity in human cancer, with an emphasis on features relevant to intact tumors and therapeutic liabilities. Citation Format: Ralph J. DeBerardinis. Metabolic complexity in cancer cells and tumors [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr IA23.
Longitudinal Replication Of Severe Asthma Exhaled Breath Phenotypes By The U-Biopred Electronic Nose Platform
Authors: P. Brinkman, A. H. Wagener, P. P Hekking, A. T. Bansal, Y. Wang, H. Weda, H. H. Knobel, T. J. Vink, N. J. Rattray, A. D'Amico, G. Pennazza, M. Santonico, P. S. Bakke, M. Caruso, K. F. Chung, J. Corfield, S. E Dahlen, R. Djukanovic, T. Geiser, I. Horvath, N. Krug, J. Musial, D. E. Shaw, I. Pandis, T. Sandström, A. R. Sousa, P. Montuschi, S. J. Fowler, P. J. Sterk
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Longitudinal Replication Of Severe Asthma Exhaled Breath Phenotypes By The U-Biopred Electronic Nose Platform
Abstract 19601: Barriers to Patient Self-Assessment of Coronary Disease Risk: A Public Health Challenge
Authors: Tanya Kakkar, Niveditha Pattathil, Puru Panchal, Cameron Taheri, Catherine Kreatsoulas
Journal: Circulation (2017)

Introduction/Objective: Patients’ understanding of cardiovascular disease risk factors (CVDRF) has important implications in the adherence to treatment and trajectory of their care. We sought to un...
Recommendations for the Appropriate Structure, Communication, and Investigation of Tobacco Harm Reduction Claims. An Official American Thoracic Society Policy Statement
Authors: Frank T. Leone, Kai-Håkon Carlsen, David Chooljian, Laura E. Crotty Alexander, Frank C. Detterbeck, Michelle N. Eakin, Sarah Evers-Casey, Harold J. Farber, Patricia Folan, Hasmeena Kathuria, Karen Latzka, Shane McDermott, Sharon McGrath-Morrow, Farzad Moazed, Alfred Munzer, Enid Neptune, Smita Pakhale, David P. L. Sachs, Jonathan Samet, Beth Sufian, Dona Upson
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsRecommendationsDiscussionPatient PerspectiveReferencesCITING ARTICLES
Abstract 14633: Cardiopulmonary Exercise Testing as a Predictor of Liver Disease in Fontan Patients: Two Tertiary Center Experience
Authors: Anushree Agarwal, Colin Cunnington, Aarthi Sabanayagam, Lucas Zier, Charles E McCulloch, Ian S Harris, Elyse Foster, Dougal Atkinson, Angela Bryan, Petra Jenkins, Jaspal Dua, Michael J Parker, Devinda Karunaratne, John Moore, Jeffrey Meadows, Bernard Clarke, Andreas Hoschtitzky, Vaikom S Mahadevan
Journal: Circulation (2016)

Introduction: Liver disease (LD) is a known long-term complication in single ventricle patients who undergo Fontan procedures. Cardiopulmonary exercise test (CPET) variables are known to be associa...
Triple therapy <i>versus</i> single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
Authors: Mario Cazzola, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera
Journal: European Respiratory Journal (2018)

We performed a meta-analysis to compare the impact of triple combination therapy with inhaled corticosteroids (ICS), long-acting β 2 -agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs) versus LABA/LAMA combination therapy or single long-acting bronchodilator therapy in chronic obstructive pulmonary disease. The ICS/LABA/LAMA combination reduced the risk of exacerbation (relative risk 0.70, 95% CI 0.53–0.94) and improved trough forced expiratory volume in 1 s (mean difference in mL +37.94, 95% CI 18.83–53.89) versus LABA/LAMA combination therapy. The protective effect of triple combination therapy versus LABA/LAMA combination therapy against risk of exacerbation was greater in patients with blood eosinophil counts ≥300 cells·µL −1 (relative risk 0.57, 95% CI 0.48–0.68). While ∼38 patients had to be treated for 1 year with ICS/LABA/LAMA combination therapy to prevent one exacerbation compared to LABA/LAMA combination therapy, the number needed to treat (NNT) was ∼21 when compared to single long-acting bronchodilator therapy. The person-based NNT per year of ICS/LABA/LAMA combination therapy versus LABA/LAMA combination therapy was significantly (p&lt;0.05) lower in patients with eosinophil counts ≥300 cells·µL −1 (NNT value: 8.58) than in those with counts &lt;300 cells·µL −1 (NNT value: 46.28). The risk of pneumonia did not differ between ICS/LABA/LAMA combination therapy and its comparators. The number needed to harm was ∼195. This meta-analysis suggests that patients on single long-acting bronchodilator therapy or LABA/LAMA combination therapy, who still have exacerbations and have blood eosinophil counts ≥300 cells·µL −1 , could benefit from ICS/LABA/LAMA combination therapy.
The use of broad-range bacterial PCR in the diagnosis of infectious diseases: a prospective cohort study
Authors: J. Tkadlec, M. Peckova, L. Sramkova, V. Rohn, D. Jahoda, D. Raszka, J. Berousek, F. Mosna, T. Vymazal, M. Kvapil, P. Drevinek
Journal: Clinical Microbiology and Infection (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Authors: Dionysos Slaga, Diego Ellerman, T. Noelle Lombana, Rajesh Vij, Ji Li, Maria Hristopoulos, Robyn Clark, Jennifer Johnston, Amy Shelton, Elaine Mai, Kapil Gadkar, Amy A. Lo, James T. Koerber, Klara Totpal, Rodney Prell, Genee Lee, Christoph Spiess, Teemu T. Junttila
Journal: Science Translational Medicine (2018)

T cell–dependent bispecific antibodies with bivalent low affinity binding to HER2 are more selective for tumor cells that overexpress the target.
Initial formation of corrosion products on pure zinc in saline solution
Authors: Yao Meng, Lijun Liu, Dawei Zhang, Chaofang Dong, Yu Yan, Alex A. Volinsky, Lu-Ning Wang
Journal: Bioactive Materials (2018)

Corrosion product formed on zinc sample during 2 weeks immersion in saline solution has been investigated. The corrosion layer morphology as well as its chemical composition, was analyzed using scanning electron microscopy (SEM), x-ray diffraction (XRD), x-ray photoelectron spectroscopy (XPS) and Fourier transform infrared spectroscopy (FTIR). Electrochemical measurement was used to analyze the corrosion behavior. Zinc oxide, zinc hydroxide and zinc hydroxide chloride were formed on zinc surface in saline solution. The thickness of corrosion layer increased with the time increased. The pure Zn has an estimated corrosion rate of 0.063 mm y−1 after immersion for 336 h. Probable mechanisms of zinc corrosion products formation are presented.
Renal replacement therapy: summary of NICE guidance
Authors: James Gilbert, Kate Lovibond, Andrew Mooney, Jan Dudley
Journal: BMJ (2018)

### What you need to know Approximately 8000 people a year start renal replacement therapy in the UK.1 Box 1 describes the options available for people approaching the need for renal replacement therapy. Around 60 000 people are currently living with a kidney transplant or are receiving dialysis. Transplant is the most common form of renal replacement therapy (approximately 54% of prevalent renal replacement therapy patients), followed by haemodialysis (40%), and then peritoneal dialysis (6%).1 The number of new transplants was around 3000 in 2016; this has gradually increased more recently. Some people will receive a kidney from a living donor, but those who have to join the waiting list for a kidney donation can expect to wait for 2.5-3 years.2 Among those receiving dialysis, most people opt for haemodialysis or haemodiafiltration done at hospital or in a satellite centre rather than at home. Box 1 ### Renal replacement therapy explained Renal replacement therapy comprises either transplantation or dialysis. Some people decide not to receive renal replacement therapy but choose conservative management, which comprises full supportive management (including advance care planning and control of symptoms and complications). #### TransplantationRETURN TO TEXT
Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
Authors: B.I. Rini, N.M. Tannir, B. Escudier, D.F. McDermott, M.-O. Grimm, C. Porta, T. Powles, C.K. Kollmannsberger, H.P. Gurney, S.S. Tykodi, M. Harrison, D.Y.C. Heng, V. Grünwald, T.K. Choueiri, S. Mekan, M.B. McHenry, H.J. Hammers, R.J. Motzer, S. George
Journal: Annals of Oncology (2018)
GW29-e0964 Electrocardiographic Biomarkers for Prediction of Coronary Artery Disease: The Atherosclerosis Risk in Communities Study
Authors: Xiaodong Zhuang, Fengjiao Yan, Lizhen Liao, Shaozhao Zhang, Huimin Zhou, Xiuting Sun, Xiangbin Zhong, Wujun Zhang, Zhimin Du, Xinxue Liao
Journal: Journal of the American College of Cardiology (2018)
Abstract 16843: Early Preconditioning Reduces No-reflow Independently of Infarct Size in Prolonged Ischemia and Benefits Cardiac Remodeling in Mouse
Authors: Yibing Nong, Yiru Guo, Xiaoping Zhu, Alex Tomlin, Roberto Bolli
Journal: Circulation (2017)

Coronary microvascular no-reflow commonly coexists with infarcted cardiomyocyte in reperfused myocardium. Recent studies point to microcirculation as a target, different from infarction size, in ca...
Brexit: hospitals told to identify contracts that could be affected by “no deal”
Authors: Gareth Iacobucci
Journal: BMJ (2018)

The UK government has told NHS hospitals in England to draw up a list of all contracts that could be affected in the event of the UK failing to negotiate a deal to exit from the European Union.

In a letter to all NHS trust chief executives and heads of procurement on 12 October, the health and social care secretary for England, Matt Hancock, instructed all hospitals to provide the department with a list of contracts where the supply chain was …
Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies
Authors: Yuichi Ando, Toshihiko Doi, Ayako Mitsuma, Takefumi Mizutani, Masanori Toyoda, Yoshinori Imamura, Naomi Kiyota, Yoichi Naito, Nobuaki Matsubara, Kae Ishihara, Takeshi Tajima, Kota Tokushige, Scott Cameron, Hironobu Minami
Journal: Annals of Oncology (2018)
Association of the rs1883832 variant of CD40 with NSCLC risk and overall survival
Authors: F.-I.D. Dimitrakopoulos, A. Antonacopoulou, A. Kottorou, S. Marousi, I. Koukourikou, C. Scopa, D. Dougenis, V. Tzelepi, H. Kalofonos
Journal: Annals of Oncology (2018)
GW29-e1916 Contrast-enhanced Ultrasound for Surveillance of Endoleak after Endovascular Abdominal Aortic Aneurysm Repair：A case report and review of the literature
Authors: Yangyang Lei, Wenjuan Tong, Meiqing Cheng, Shaohong Wu, Zuanan Chen, Xiaoyan Xie, Yanling Zheng
Journal: Journal of the American College of Cardiology (2018)
Abstract 15943: In vivo Assessment of Thrombus Formation Without Coronary Plaque Rupture by Optical Coherence Tomography
Authors: Toshiyuki Iwai, Taishi Yonetsu, Tetsumin Lee, Tadashi Murai, Kenji Koura, Takamitsu Takagi, Tsunekazu Kakuta
Journal: Circulation (2011)

Backgrounds: Coronary plaque rupture and subsequent thrombus formation is a major cause of acute coronary syndrome (ACS). However, postmortem histopathological studies revealed that more than 30% o...
Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study
Authors: T. Kato, M. Kotaka, H. Satake, A. Makiyama, Y. Tsuji, K. Shinozaki, T. Fujiwara, T. Mizushima, Y. Harihara, N. Nagata, N. Kurihara, Y. Kagawa, G. Kusakawa, T. Sakai, Y. Uchida, M. Takamoto, S. Asami, M. Ando, Y. Saito, I. Hyodo
Journal: Annals of Oncology (2018)
Setting Appropriate Expectations After Bariatric Surgery
Authors: Amir A. Ghaferi, Oliver A. Varban
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience
Authors: Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, Benjamin R. Tan
Journal: Journal of the National Comprehensive Cancer Network (2018)

Background: Combined hepatocellular-cholangiocarcinoma tumors (cHCC-CCA) are a heterogeneous group of rare malignancies that have no established optimal treatment. Patients and Methods: We identified patients with cHCC-CCA treated at a tertiary center and retrospectively examined their histology, interventions, and outcomes. We calculated disease control rate (DCR), disease progression, overall survival, and progression-free survival (PFS) between treatment subgroups. Results: A total of 123 patients were evaluable. Interventions included resection, locoregional therapy, transplant, chemotherapy, and targeted agents. Ultimately, 68 patients received systemic treatment—57 with gemcitabine plus either 5-fluoropyrimidine (5-FU) or a platinum combination. Disease progression was more common in the gemcitabine/5-FU group versus gemcitabine/platinum (P=.028), whereas DCR favored gemcitabine/platinum (78.4% vs 38.5%; P=.0143). Median PFS from time of initial diagnosis favored the gemcitabine/platinum group, but the difference did not reach statistical significance. Targeted agents had minimal to no effect on survival metrics. Conclusions: Gemcitabine/platinum seems to be a superior regimen for patients with cHCC-CCA who require systemic treatment. Further studies are needed to clarify the regimen's efficacy and applicability in patient subgroups.
Samuel William Babington Newsom
Authors: Richard Newsom
Journal: BMJ (2018)

Samuel William Babington Newsom (“Bill”) was educated at Rossall School (1945-50) and Caius College (1950-3), where he developed a lifelong link to Cambridge. After undergraduate work he attended the Westminster Hospital Medical School.

He was appointed house surgeon at Addenbrooke’s Hospital, where he met his future wife, Rose Fisher. He then returned to the Westminster for house jobs, did his military …
A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)
Authors: C.H. Ng, S.B. Ting, W.Y.K. Hwang, A. Bajel, R. Eek, M. McHale, H.-J. Shih, N. McIntyre, J. Kwek, B. Lindmark
Journal: Annals of Oncology (2018)
The Chemosensory Function of Primary Cilia Regulates Cholangiocyte Migration, Invasion, and Tumor Growth
Authors: Adrian P. Mansini, Estanislao Peixoto, Sujeong Jin, Seth Richard, Sergio A. Gradilone
Journal: Hepatology (2018)

Cholangiocytes, the epithelial cells lining the biliary tree in the liver, express primary cilia that can detect several kinds of environmental signals and then transmit this information into the cell. We have reported that cilia are significantly reduced in cholangiocarcinoma (CCA) and that the experimental deciliation of normal cells induces a malignant‐like phenotype with increased proliferation, anchorage‐independent growth, invasion, and migration. Here, we tested the hypothesis that the chemosensory function of cholangiocyte primary cilia acts as a mechanism for tumor suppression. We found that in the presence of extracellular nucleotides cilia‐dependent chemosensation of the nucleotides inhibited migration and invasion in normal ciliated cholangiocytes through a P2Y11 receptor and liver kinase B1 (LKB1)–phosphatase and tensin homolog–AKT–dependent mechanism. In contrast, in normal deciliated cholangiocytes and CCA cells, the nucleotides induced the opposite effects, i.e., increased migration and invasion. As activation of LKB1 through a cilia‐dependent mechanism was required for the nucleotide‐mediated inhibitory effects on migration and invasion, we attempted to activate LKB1 directly, independent of ciliary expression, using the compound hesperidin methyl chalcone (HMC). We found that HMC induced activation of LKB1 in both ciliated and deciliated cells in vitro , resulting in the inhibition of migration and proliferation. Furthermore, using a rat syngeneic orthotopic CCA model, we found that HMC inhibited tumor growth in vivo . Conclusion: These findings highlight the importance of the chemosensory function of primary cilia for the control of migration and invasion and suggest that, by directly activating LKB1 and bypassing the need for primary cilia, it is possible to emulate this chemosensory function in CCA cells; these data warrant further studies evaluating the possibility of using HMC as therapy for CCA.
Single-allele chromatin interactions identify regulatory hubs in dynamic compartmentalized domains
Authors: A. Marieke Oudelaar, James O. J. Davies, Lars L. P. Hanssen, Jelena M. Telenius, Ron Schwessinger, Yu Liu, Jill M. Brown, Damien J. Downes, Andrea M. Chiariello, Simona Bianco, Mario Nicodemi, Veronica J. Buckle, Job Dekker, Douglas R. Higgs, Jim R. Hughes
Journal: Nature Genetics (2018)
THU0560 Chronic recurrent multifocal osteomyelitis: four tertiary spanish hospitals experience. a multicentric study
Authors: A. García Fernández, J. Arroyo Palomo, D. Clemente Garrulo, B. Serrano Benavente, J. Novoa Medina, J.C. Nieto González, S. Machín García, A.M. Brandy García, J.C. López Robledillo, I. Monteagudo Sáez, A.L. Boteanu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory polygenic bone disease characterised by aseptic bone inflammation in paediatric population. Its management, clinical, radiological findings and treatment have not yet been standardised. <h3>Objectives</h3> Retrospective, descriptive multicentric study of patients diagnosed of CRMO in four tertiary level hospitals' paediatric rheumatology section. There were 16 patients included. The clinical, radiological characteristics where analysed as well as response to treatment options. <h3>Results</h3> The median age at diagnosis was 10,5 years, female:male ratio 62,5:37,5%. The delay in the diagnosis had a median of 4.5 months, being less than one year in 11 patients. Bone pain was the first symptom in 100% of the patients accompanied by fever in 25% of them. A single patient presented perilesional arthritis. A slight-moderate increase on acute fase reactants was observed at the debut of the disease: median ESR 47.5 mm/h. The median number of locations at debut was 2.5 (range 1–14), with multifocal involvement in 75%. The most frequent location was tibia (56%), followed by pelvis (44%) and vertebrae (31,25%). Other locations less fenquent were: carpus (12.5%), femur (12.5%) mandible (6%) and sternum (6%). Biopsy was performed in 14/16 patients and bone scintigraphy with Tc99 in 12/16 patients, with pathological uptake observed in 91.6% of cases. MRI was the radiological test of suspected diagnosis in 15/16 patients. NSAIDs were the initial treatment. 5 patients received different antibiotic therapy regimens<i>,</i> without clinical or radiological improvement. 56.25% of patients required other treatments. Systemic corticosteroids were used in 12.5% of patients and bisphosphonates in 43.75% (100% of patients with axial involvement). After 6 months of treatment with biphosphonates, 57.14% had complete remission, 28.57% partial remission and 14.28% worsening. 12.5% of the patients had a torpid evolution, receiving sequential therapies with multiple synthetic or biological DMARDs (Anakinra, Canakinumab, Etanercept), and another 12.5% required surgery. <h3>Conclusions</h3> The diagnosis of CRMO is a challenge in the absence of pathognomonic features which leads to delay in diagnosis and the initiation of treatment. In our centres the biphosphonates were the treatment strategy used in patients with spinal involvement with 85.67% response at 6 moths. <h3>Disclosure of Interest</h3> None declared